

Bradley Aaron Krasnick

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8466923/publications.pdf>

Version: 2024-02-01

75
papers

1,625
citations

257450

24
h-index

345221

36
g-index

76
all docs

76
docs citations

76
times ranked

2224
citing authors

#	ARTICLE	IF	CITATIONS
1	Development and Validation of a Modified Eighth AJCC Staging System for Primary Pancreatic Neuroendocrine Tumors. <i>Annals of Surgery</i> , 2022, 275, e773-e780.	4.2	13
2	Extremity Soft Tissue Sarcoma: A Multi-Institutional Validation of Prognostic Nomograms. <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	5
3	ASO Visual Abstract: Extremity Soft Tissue Sarcoma—A Multi-institutional Validation of Prognostic Nomograms. <i>Annals of Surgical Oncology</i> , 2022, 29, 3304.	1.5	0
4	DANSR: A Tool for the Detection of Annotated and Novel Small RNAs. <i>Non-coding RNA</i> , 2022, 8, 9.	2.6	0
5	Long-Term Outcomes after Spleen-Preserving Distal Pancreatectomy for Pancreatic Neuroendocrine Tumors: Results from the US Neuroendocrine Study Group. <i>Neuroendocrinology</i> , 2021, 111, 129-138.	2.5	12
6	Indications and outcomes of enucleation versus formal pancreatectomy for pancreatic neuroendocrine tumors. <i>Hpb</i> , 2021, 23, 413-421.	0.3	18
7	Identifying Risk Factors and Patterns for Early Recurrence of Pancreatic Neuroendocrine Tumors: A Multi-Institutional Study. <i>Cancers</i> , 2021, 13, 2242.	3.7	6
8	Memory-like Differentiation Enhances NK Cell Responses to Melanoma. <i>Clinical Cancer Research</i> , 2021, 27, 4859-4869.	7.0	33
9	Isotope tracing in adult zebrafish reveals alanine cycling between melanoma and liver. <i>Cell Metabolism</i> , 2021, 33, 1493-1504.e5.	16.2	29
10	A multi-institutional validation study of prognostic nomograms for retroperitoneal sarcoma. <i>Journal of Surgical Oncology</i> , 2021, 124, 829-837.	1.7	9
11	A novel preoperative risk score to guide patient selection for resection of soft tissue sarcoma lung metastases: An analysis from the United States Sarcoma Collaborative. <i>Journal of Surgical Oncology</i> , 2021, 124, 1477-1484.	1.7	7
12	Resection of pancreatic neuroendocrine tumors: defining patterns and time course of recurrence. <i>Hpb</i> , 2020, 22, 215-223.	0.3	20
13	Trends in the Use of Adjuvant Chemotherapy for High-Grade Truncal and Extremity Soft Tissue Sarcomas. <i>Journal of Surgical Research</i> , 2020, 245, 577-586.	1.6	3
14	Tumor burden score predicts tumor recurrence of non-functional pancreatic neuroendocrine tumors after curative resection. <i>Hpb</i> , 2020, 22, 1149-1157.	0.3	13
15	Impact of perioperative blood transfusion on survival in pancreatic neuroendocrine tumor patients: analysis from the US Neuroendocrine Study Group. <i>Hpb</i> , 2020, 22, 1042-1050.	0.3	5
16	Trends in the Number of Lymph Nodes Evaluated Among Patients with Pancreatic Neuroendocrine Tumors in the United States: A Multi-Institutional and National Database Analysis. <i>Annals of Surgical Oncology</i> , 2020, 27, 1203-1212.	1.5	21
17	Analysis of textbook outcomes among patients undergoing resection of retroperitoneal sarcoma: A multi-institutional analysis of the US Sarcoma Collaborative. <i>Journal of Surgical Oncology</i> , 2020, 122, 1189-1198.	1.7	19
18	A closer look at the natural history and recurrence patterns of high-grade truncal/extremity leiomyosarcomas: A multi-institutional analysis from the US Sarcoma Collaborative. <i>Surgical Oncology</i> , 2020, 34, 292-297.	1.6	2

#	ARTICLE	IF	CITATIONS
19	Long non-coding RNA RAMS11 promotes metastatic colorectal cancer progression. <i>Nature Communications</i> , 2020, 11, 2156.	12.8	83
20	The clonal evolution of metastatic colorectal cancer. <i>Science Advances</i> , 2020, 6, eaay9691.	10.3	41
21	Neoadjuvant radiation improves margin-negative resection rates in extremity sarcoma but not survival. <i>Journal of Surgical Oncology</i> , 2020, 121, 1249-1258.	1.7	9
22	Specific Growth Rate as a Predictor of Survival in Pancreatic Neuroendocrine Tumors: A Multi-institutional Study from the United States Neuroendocrine Study Group. <i>Annals of Surgical Oncology</i> , 2020, 27, 3915-3923.	1.5	2
23	Impact of Insurance Status on Survival in Gastroenteropancreatic Neuroendocrine Tumors. <i>Annals of Surgical Oncology</i> , 2020, 27, 3147-3153.	1.5	4
24	Predictors of Disease-Free and Overall Survival in Retroperitoneal Sarcomas: A Modern 16-Year Multi-Institutional Study from the United States Sarcoma Collaboration (USSC). <i>Sarcoma</i> , 2019, 2019, 1-8.	1.3	11
25	Tumor Ablation Using 3-Dimensional Electromagnetic-Guided Ultrasound Versus Standard Ultrasound in a Porcine Model. <i>Surgical Innovation</i> , 2019, 26, 420-426.	0.9	4
26	The role of radiation therapy and margin width in localized soft-tissue sarcoma: Analysis from the US Sarcoma Collaborative. <i>Journal of Surgical Oncology</i> , 2019, 120, 325-331.	1.7	16
27	Defining the Role of Lymphadenectomy for Pancreatic Neuroendocrine Tumors: An Eight-Institution Study of 695 Patients from the US Neuroendocrine Tumor Study Group. <i>Annals of Surgical Oncology</i> , 2019, 26, 2517-2524.	1.5	38
28	Minimally invasive versus open distal pancreatectomy for pancreatic neuroendocrine tumors: An analysis from the U.S. neuroendocrine tumor study group. <i>Journal of Surgical Oncology</i> , 2019, 120, 231-240.	1.7	29
29	Association of Perioperative Transfusion with Recurrence and Survival After Resection of Distal Cholangiocarcinoma: A 10-Institution Study from the US Extrahepatic Biliary Malignancy Consortium. <i>Annals of Surgical Oncology</i> , 2019, 26, 1814-1823.	1.5	19
30	Evaluating the ACS NSQIP Risk Calculator in Primary Pancreatic Neuroendocrine Tumor: Results from the US Neuroendocrine Tumor Study Group. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 2225-2231.	1.7	10
31	Evaluating the ACS-NSQIP Risk Calculator in Primary GI Neuroendocrine Tumor: Results from the United States Neuroendocrine Tumor Study Group. <i>American Surgeon</i> , 2019, 85, 1334-1340.	0.8	7
32	New Nodal Staging for Primary Pancreatic Neuroendocrine Tumors. <i>Annals of Surgery</i> , 2019, Publish Ahead of Print, e28-e35.	4.2	36
33	Staging laparoscopy among three subtypes of extrahepatic biliary malignancy: a 15-year experience from 10 institutions. <i>Journal of Surgical Oncology</i> , 2019, 119, 288-294.	1.7	12
34	Surgery Provides Long-Term Survival in Patients with Metastatic Neuroendocrine Tumors Undergoing Resection for Non-Hormonal Symptoms. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 122-134.	1.7	22
35	Influence of carcinoid syndrome on the clinical characteristics and outcomes of patients with gastroenteropancreatic neuroendocrine tumors undergoing operative resection. <i>Surgery</i> , 2019, 165, 657-663.	1.9	16
36	Actual 5-Year Survivors After Surgical Resection of Hilar Cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2019, 26, 611-618.	1.5	34

#	ARTICLE	IF	CITATIONS
37	Margin status and long-term prognosis of primary pancreatic neuroendocrine tumor after curative resection: Results from the US Neuroendocrine Tumor Study Group. <i>Surgery</i> , 2019, 165, 548-556.	1.9	39
38	Precision delivery of RAS-inhibiting siRNA to KRAS driven cancer via peptide-based nanoparticles. <i>Oncotarget</i> , 2019, 10, 4761-4775.	1.8	45
39	Evaluating the ACS-NSQIP Risk Calculator in Primary GI Neuroendocrine Tumor: Results from the United States Neuroendocrine Tumor Study Group. <i>American Surgeon</i> , 2019, 85, 1334-1340.	0.8	3
40	IL23 and TGF- β diminish macrophage associated metastasis in pancreatic carcinoma. <i>Scientific Reports</i> , 2018, 8, 5808.	3.3	16
41	Nomogram predicting the risk of recurrence after curative-intent resection of primary non-metastatic gastrointestinal neuroendocrine tumors: An analysis of the U.S. Neuroendocrine Tumor Study Group. <i>Journal of Surgical Oncology</i> , 2018, 117, 868-878.	1.7	36
42	Outcomes after vascular resection during curative-intent resection for hilar cholangiocarcinoma: a multi-institution study from the US extrahepatic biliary malignancy consortium. <i>Hpb</i> , 2018, 20, 332-339.	0.3	27
43	Adjuvant therapy is associated with improved survival after curative resection for hilar cholangiocarcinoma: A multi-institution analysis from the U.S. extrahepatic biliary malignancy consortium. <i>Journal of Surgical Oncology</i> , 2018, 117, 363-371.	1.7	36
44	Transplantation Versus Resection for Hilar Cholangiocarcinoma. <i>Annals of Surgery</i> , 2018, 267, 797-805.	4.2	137
45	Recruitment of CCR2 ⁺ tumor associated macrophage to sites of liver metastasis confers a poor prognosis in human colorectal cancer. <i>Oncolmmunology</i> , 2018, 7, e1470729.	4.6	88
46	Association of perioperative transfusion with survival and recurrence after resection of gallbladder cancer: A 10-institution study from the US Extrahepatic Biliary Malignancy Consortium. <i>Journal of Surgical Oncology</i> , 2018, 117, 1638-1647.	1.7	10
47	Perioperative chemotherapy is not associated with improved survival in high-grade truncal sarcoma. <i>Journal of Surgical Research</i> , 2018, 231, 248-256.	1.6	2
48	Whipple-specific complications result in prolonged length of stay not accounted for in ACS-NSQIP Surgical Risk Calculator. <i>Hpb</i> , 2017, 19, 147-153.	0.3	36
49	Routine port-site excision in incidentally discovered gallbladder cancer is not associated with improved survival: A multi-institution analysis from the US Extrahepatic Biliary Malignancy Consortium. <i>Journal of Surgical Oncology</i> , 2017, 115, 805-811.	1.7	28
50	Gallbladder Cancer Presenting with Jaundice: Uniformly Fatal or Still Potentially Curable?. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 1245-1253.	1.7	30
51	Surgical Site Infection Is Associated with Tumor Recurrence in Patients with Extrahepatic Biliary Malignancies. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 1813-1820.	1.7	12
52	Survival after resection of perihilar cholangiocarcinoma in patients with lymph node metastases. <i>Hpb</i> , 2017, 19, 735-740.	0.3	27
53	Defining the Chance of Statistical Cure Among Patients with Extrahepatic Biliary Tract Cancer. <i>World Journal of Surgery</i> , 2017, 41, 224-231.	1.6	19
54	Pathologic and Prognostic Implications of Incidental versus Nonincidental Gallbladder Cancer: A 10-Institution Study from the United States Extrahepatic Biliary Malignancy Consortium. <i>American Surgeon</i> , 2017, 83, 679-686.	0.8	44

#	ARTICLE	IF	CITATIONS
55	Precision delivery of RAS-inhibiting siRNA to pancreatic cancer via peptide-based nanoparticles.. Journal of Clinical Oncology, 2017, 35, 287-287.	1.6	2
56	Histologic classification and grading enhances gallbladder cancer staging: A population-based prognostic score validated by the U.S. Extrahepatic Biliary Malignancy Consortium.. Journal of Clinical Oncology, 2017, 35, 356-356.	1.6	2
57	Actual 5-year survivors following resection of hilar cholangiocarcinoma.. Journal of Clinical Oncology, 2017, 35, 352-352.	1.6	10
58	Effect of perioperative transfusion on recurrence and survival after resection of distal cholangiocarcinoma: A 10-institution study from the U.S. Extrahepatic Biliary Malignancy Consortium.. Journal of Clinical Oncology, 2017, 35, 236-236.	1.6	0
59	Anti-KRAS siRNA nanoparticles for targeted colorectal cancer therapy.. Journal of Clinical Oncology, 2017, 35, 636-636.	1.6	3
60	Assessing the impact of common bile duct resection in the surgical management of gallbladder cancer. Journal of Surgical Oncology, 2016, 114, 176-180.	1.7	30
61	Prognostic Implications of Lymph Node Status for Patients With Gallbladder Cancer: A Multi-Institutional Study. Annals of Surgical Oncology, 2016, 23, 3016-3023.	1.5	42
62	Perihilar Cholangiocarcinoma: Number of Nodes Examined and Optimal Lymph Node Prognostic Scheme. Journal of the American College of Surgeons, 2016, 222, 750-759e2.	0.5	61
63	Proposal for a new T-stage classification system for distal cholangiocarcinoma: a 10-institution study from the U.S. Extrahepatic Biliary Malignancy Consortium. Hpb, 2016, 18, 793-799.	0.3	17
64	Rates and patterns of recurrence after curative intent resection for gallbladder cancer: a multi-institution analysis from the US Extra-hepatic Biliary Malignancy Consortium. Hpb, 2016, 18, 872-878.	0.3	66
65	Changing Odds of Survival Over Time among Patients Undergoing Surgical Resection of Gallbladder Carcinoma. Annals of Surgical Oncology, 2016, 23, 4401-4409.	1.5	22
66	A Comparison of Prognostic Schemes for Perihilar Cholangiocarcinoma. Journal of Gastrointestinal Surgery, 2016, 20, 1716-1724.	1.7	31
67	Assessing Trends in Palliative Surgery for Extrahepatic Biliary Malignancies: A 15-Year Multicenter Study. Journal of Gastrointestinal Surgery, 2016, 20, 1444-1452.	1.7	16
68	Conditional probability of long-term survival after resection of hilar cholangiocarcinoma. Hpb, 2016, 18, 510-517.	0.3	33
69	Impact of Chemotherapy and External-Beam Radiation Therapy on Outcomes among Patients with Resected Gallbladder Cancer: A Multi-institutional Analysis. Annals of Surgical Oncology, 2016, 23, 2998-3008.	1.5	44
70	Gallbladder cancer presenting with jaundice: Uniformly fatal or still potentially curable?. Journal of Clinical Oncology, 2016, 34, 336-336.	1.6	1
71	Conditional survival probability of long-term survival after resection of peri-hilar cholangiocarcinoma.. Journal of Clinical Oncology, 2016, 34, 212-212.	1.6	0
72	The effect of postoperative morbidity on long-term survival after curative resection for extra-hepatic biliary tumors: A multi-institution analysis from the U.S. Extrahepatic Biliary Malignancy Consortium.. Journal of Clinical Oncology, 2016, 34, 435-435.	1.6	0

#	ARTICLE	IF	CITATIONS
73	Curative resection for hilar cholangiocarcinoma: Does adjuvant therapy impact overall survival? A multi-institution analysis from the U.S. Extrahepatic Biliary Malignancy Consortium.. Journal of Clinical Oncology, 2016, 34, 388-388.	1.6	0
74	Palliative treatment in extrahepatic biliary malignancies: A multi-institutional cohort.. Journal of Clinical Oncology, 2016, 34, 456-456.	1.6	0
75	A reappraisal of staging laparoscopy in three subtypes of cholangiocarcinoma: A multi-institution analysis from the U.S. Extrahepatic Biliary Malignancy Consortium.. Journal of Clinical Oncology, 2016, 34, 226-226.	1.6	0